The ALYREF Knockout HAP1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout population in the HAP1 near-haploid human cell line, targeting the ALYREF (THOC4) gene. This loss-of-function model enables investigation of ALYREF??s role as an mRNA export adaptor within the TREX complex. The polyclonal format provides a heterogeneous pool of gene-disrupted cells, facilitating population-based functional studies without clonal selection.
HAP1 is a chronic myeloid leukemia-derived near-haploid cell line originating from KBM-7 cells. Its near-haploid karyotype simplifies genetic manipulation and functional genomics screens, making it a favored host for CRISPR-mediated gene disruption. Originally from a male patient, HAP1 retains features relevant to hematological cancer research while offering a clear genetic background to study conserved cellular processes.
ALYREF (THOC4) is an essential adaptor that links transcription and splicing to mRNA nuclear export. As a core component of the TREX complex, it is assembled onto mRNAs during splicing via interactions with the cap-binding complex, exon junction complex, and THO complex. ALYREF then recruits the NXF1:NXT1 export receptor to escort mature mRNPs through the nuclear pore. Its activity is modulated by upstream splicing factors and the THO complex, and it binds key partners such as UAP56/URH49, TAP, and spliceosomal proteins. Downstream, ALYREF controls global and viral mRNA export, influencing transcript localization and expression.
Within HAP1 cells, ALYREF knockout is particularly informative for probing RNA export pathways in a near-haploid, oncogenic context. The CML background underscores the importance of efficient mRNA trafficking in cancer cell proliferation. Moreover, HAP1 supports studies of viral subversion, as pathogens like HIV and influenza A exploit ALYREF-dependent export. The polyclonal KO population captures a range of editing outcomes, enabling robust assessment of ALYREF dependency across various readouts.
This product is suited for diverse applications, including western blotting, RT-qPCR, and RNA-seq to assess target depletion and transcriptomic changes. Poly(A)+ RNA FISH and RNA immunoprecipitation can map mRNA localization defects, while co-immunoprecipitation clarifies TREX complex integrity. Cell viability and viral replication assays further evaluate functional consequences in cancer and infection models. By integrating these techniques, researchers can delineate ALYREF-dependent mRNA networks and explore therapeutic targets. For details, contact Ascent Research.
